Dan Spiegelman is an accomplished executive with extensive commercial, financial and strategic leadership experience during an extensive career in the pharmaceutical industry, with a specific focus on rare diseases. Dan previously served as Executive Vice President and Chief Financial Officer of BioMarin. Prior to BioMarin, he served as a consultant to provide strategic financial management support to a portfolio of public and private life science companies. Prior to his consultancy, Dan served as Senior Vice President and Chief Financial Officer of CV Therapeutics. Prior to CV Therapeutics, he served in various roles at Genentech, most recently as Treasurer.

Mr. Spiegelman currently serves on the boards of directors for Myriad Genetics, Recardia Therapeutics and Tizona Therapeutics. He received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.